Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-week, Multi-centre, Randomised, Double-blind (Participant and Investigator), Placebo-controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 in Patients With Major Depressive Disorder

NCT06558344 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06558344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06558344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-week, Multi-centre, Randomised, Double-blind (Participant and Investigator), Placebo-controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 in Patients With Major Depressive Disorder
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2024
Completion date
May 12, 2025
Enrollment
225 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major